Exercise and medicine study for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a specific type of PAH (Group 1) diagnosed by a heart catheter test
- Your PAH symptoms are mild to moderate (WHO class II or III)
- You are on stable PAH medications for at least 3 months and your doctor plans to start you on sotatercept
- You are willing and able to do a home exercise program for 24 weeks with remote monitoring
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
This trial tests how a new medication, sotatercept, affects the heart and lungs in people with pulmonary arterial hypertension (PAH). Using a special scan, the study looks at how the drug changes the blood vessels and heart over time to see if it helps.
This trial tests a home-based exercise program delivered through a smartphone app for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrowed, making the heart work harder. The program aims to improve physical function and quality of life through guided telerehabilitation.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Hear when a new Exercise Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.